Benfluorex
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 596290

CAS#: 23602-78-0

Description: Benfluorex Hydrochloride, a hypolipidemic and an anorectic agent, has been considered to treat people with type 2 diabetes by improving glycemic control and decreasing insulin resistance.

Chemical Structure

img
Benfluorex
CAS# 23602-78-0
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 596290
Name: Benfluorex
CAS#: 23602-78-0
Chemical Formula: C19H20F3NO2
Exact Mass: 351.14
Molecular Weight: 351.360
Elemental Analysis: C, 64.95; H, 5.74; F, 16.22; N, 3.99; O, 9.11

Price and Availability

Size Price Availability Quantity
5g USD 360 2 weeks
50g USD 1560 2 weeks
Bulk inquiry

Synonym: Benfluorex; BRN 4152887; JP 992; SE 780; Minolip; Mediator; EINECS 245-777-9; Benfluramate;

IUPAC/Chemical Name: 2-((1-(3-(trifluoromethyl)phenyl)propan-2-yl)amino)ethyl benzoate

InChi Key: CJAVTWRYCDNHSM-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H20F3NO2/c1-14(12-15-6-5-9-17(13-15)19(20,21)22)23-10-11-25-18(24)16-7-3-2-4-8-16/h2-9,13-14,23H,10-12H2,1H3

SMILES Code: FC(C1=CC(CC(NCCOC(C2=CC=CC=C2)=O)C)=CC=C1)(F)F

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:
Product Data
Instruction:
View handling instruction
Biological target: Benfluorex is a hepatic nuclear factor 4 alpha (HNF4α) activator.
In vitro activity: Benfluorex had an inhibitory activity on the incorporation of 14C-acetate and of 14C-HMG-CoA into non-saponifiable lipids in human blood mononuclear cells incubated in lipid-deficient medium. The lack of effect on the incorporation of 14C-mevalonate into non-saponifiable lipids strongly suggested that the reduction of sterol biosynthesis was mainly due to the inhibition of HMG-CoA reductase activity. Reference: Drugs Exp Clin Res. 1986;12(11):923-7. https://pubmed.ncbi.nlm.nih.gov/3816510/
In vivo activity: The effect of chronic (20 days) oral administration of benfluorex (35 mg/kg) in a rat model of NIDDM, induced by injection of STZ 5 days after birth and characterized by frank hyperglycemia, hypoinsulinemia, and hepatic and peripheral insulin resistance, was examined. Basal blood glucose and insulin levels, glucose tolerance and glucose-induced insulin release in vivo, and basal and insulin-stimulated in vivo glucose production and glucose utilization were examined. In the benfluorex-treated diabetic rats, postabsorptive basal plasma glucose levels were decreased (8.1 +/- 0.2 mM compared with 10.5 +/- 0.5 mM in the pair-fed untreated diabetic rats and 6.1 +/- 0.2 mM in the benfluorex-treated nondiabetic rats), whereas the basal and glucose-stimulated intravenous glucose tolerance test plasma insulin levels were not improved. In the pair-fed untreated diabetic rats, the basal glucose production and overall glucose utilization were significantly increased. In the benfluorex-treated diabetic rats, the basal glucose production and basal overall glucose utilization were normalized. After hyperinsulinemia, glucose production was normally suppressed, whereas overall glucose utilization was not significantly improved. Reference: Diabetes. 1993 Apr;42(4):564-70. https://diabetes.diabetesjournals.org/content/42/4/564.long

Preparing Stock Solutions

The following data is based on the product molecular weight 351.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: 1. Sommariva D, Blasi F, Cosentini R, Berruto M. Effects of benfluorex on sterol biosynthesis in incubated human blood mononuclear cells. Drugs Exp Clin Res. 1986;12(11):923-7. PMID: 3816510. 2. Serradas P, Blondel O, Bailbe D, Portha B. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes. 1993 Apr;42(4):564-70. doi: 10.2337/diab.42.4.564. PMID: 8454107.
In vitro protocol: 1. Sommariva D, Blasi F, Cosentini R, Berruto M. Effects of benfluorex on sterol biosynthesis in incubated human blood mononuclear cells. Drugs Exp Clin Res. 1986;12(11):923-7. PMID: 3816510.
In vivo protocol: 1. Serradas P, Blondel O, Bailbe D, Portha B. Benfluorex normalizes hyperglycemia and reverses hepatic insulin resistance in STZ-induced diabetic rats. Diabetes. 1993 Apr;42(4):564-70. doi: 10.2337/diab.42.4.564. PMID: 8454107.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: McGee M, Whitehead N, Martin J, Collins N. Drug-associated pulmonary arterial hypertension. Clin Toxicol (Phila). 2018 Mar 6:1-9. doi: 10.1080/15563650.2018.1447119. [Epub ahead of print] PubMed PMID: 29508628.

2: Eugène M, Bruneval P, Bonnet N, Attias D. Benfluorex-induced severe primary tricuspid and mitral regurgitation requiring a double-valve replacement. Eur J Cardiothorac Surg. 2018 Feb 12. doi: 10.1093/ejcts/ezy032. [Epub ahead of print] PubMed PMID: 29444226.

3: Wang S, Chen J, Jiang D, Zhang Q, You C, Tocher DR, Monroig Ó, Dong Y, Li Y. Hnf4α is involved in the regulation of vertebrate LC-PUFA biosynthesis: insights into the regulatory role of Hnf4α on expression of liver fatty acyl desaturases in the marine teleost Siganus canaliculatus. Fish Physiol Biochem. 2018 Jun;44(3):805-815. doi: 10.1007/s10695-018-0470-8. Epub 2018 Jan 19. PubMed PMID: 29352428.

4: Harris AP, Ismail KA, Nunez M, Martopullo I, Lencinas A, Selmin OI, Runyan RB. Trichloroethylene perturbs HNF4a expression and activity in the developing chick heart. Toxicol Lett. 2018 Mar 15;285:113-120. doi: 10.1016/j.toxlet.2017.12.027. Epub 2018 Jan 4. PubMed PMID: 29306027; PubMed Central PMCID: PMC5803365.

5: Wang SL, Dong WB, Dong XL, Zhu WM, Wang FF, Han F, Yan X. Comparison of twelve single-drug regimens for the treatment of type 2 diabetes mellitus. Oncotarget. 2017 Aug 16;8(42):72700-72713. doi: 10.18632/oncotarget.20282. eCollection 2017 Sep 22. PubMed PMID: 29069819; PubMed Central PMCID: PMC5641162.

6: Dyer O. France to prosecute its drug regulator and Servier in scandal over diabetes drug. BMJ. 2017 Sep 11;358:j4231. doi: 10.1136/bmj.j4231. PubMed PMID: 28893847.

7: Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, Hechler B, Gachet C, Guyonnet J, Rouillard H, Stoltz J, Quentin E, Banas S, Daubeuf F, Frossard N, Gasser B, Mazzucotelli JP, Hermine O, Maroteaux L, Monassier L. The role of 5-HT(2B) receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. Br J Pharmacol. 2017 Nov;174(22):4123-4139. doi: 10.1111/bph.13981. Epub 2017 Oct 15. PubMed PMID: 28806488; PubMed Central PMCID: PMC5680644.

8: Nau JY. Miscellanées sexuelles, hypertensives et cinématographiques. Rev Med Suisse. 2016 Sep 21;12(531):1590-1591. French. PubMed PMID: 28678460.

9: Baufreton C, Bruneval P, Rousselet MC, Ennezat PV, Fouquet O, Giraud R, Banfi C. Fatal postoperative systemic pulmonary hypertension in benfluorex-induced valvular heart disease surgery: A case report. Medicine (Baltimore). 2017 Jan;96(2):e4985. doi: 10.1097/MD.0000000000004985. PubMed PMID: 28079786; PubMed Central PMCID: PMC5266148.

10: Scheffer P, Guy-Coichard C, Outh-Gauer D, Calet-Froissart Z, Boursier M, Mintzes B, Borde JS. Conflict of Interest Policies at French Medical Schools: Starting from the Bottom. PLoS One. 2017 Jan 9;12(1):e0168258. doi: 10.1371/journal.pone.0168258. eCollection 2017. PubMed PMID: 28068362; PubMed Central PMCID: PMC5221756.

11: Le Ven F, Alavi Z, Jobic Y, Etienne Y, Didier R, Porcher R. Drug-Induced- or Rheumatic- Valvular Heart Disease in Patients Exposed to Benfluorex? PLoS One. 2016 Aug 3;11(8):e0160011. doi: 10.1371/journal.pone.0160011. eCollection 2016. PubMed PMID: 27487042; PubMed Central PMCID: PMC4972394.

12: Mendes D, Alves C, Batel Marques F. Testing the usefulness of the number needed to treat to be harmed (NNTH) in benefit-risk evaluations: case study with medicines withdrawn from the European market due to safety reasons. Expert Opin Drug Saf. 2016 Oct;15(10):1301-12. doi: 10.1080/14740338.2016.1217989. Epub 2016 Aug 5. PubMed PMID: 27467204.

13: Ennezat PV, Bruneval P, Czitrom D, Gueffet JP, Piriou N, Trochu JN, Patra O, Blanchard-Lemoine B, du Fretay XH, Nazeyrollas P, Assoun B, Jobic Y, Brochet E, Bogino E, Roudaut R, Augier C, Greffe L, Petit-Eisenmann H, Dambrin C, Chavanon O, Guillou L, Grisoli D, Morera P, Banfi C, Remadi JP, Fabre O, Vincentelli A, Lantuejoul S, Ikoli JF, Copin MC, Malergue MC, Maréchaux S, Tribouilloy C. Drug-induced aortic valve stenosis: An under recognized entity. Int J Cardiol. 2016 Oct 1;220:429-34. doi: 10.1016/j.ijcard.2016.06.112. Epub 2016 Jun 23. PubMed PMID: 27390966.

14: Bagheri H, Lacroix I, Guitton E, Damase-Michel C, Montastruc JL. Cyberpharmacovigilance: What is the usefulness of the social networks in pharmacovigilance? Therapie. 2016 Apr;71(2):235-9. doi: 10.1016/j.therap.2015.09.002. Epub 2016 Mar 28. English, French. PubMed PMID: 27080844.

15: Degrassat-Théas A, Bocquet F, Sinègre M, Peigné J, Paubel P. The "Temporary Recommendations for Use": A dual-purpose regulatory framework for off-label drug use in France. Health Policy. 2015 Nov;119(11):1399-405. doi: 10.1016/j.healthpol.2015.09.003. Epub 2015 Sep 25. PubMed PMID: 26455642.

16: Russo G, Barbato F, Grumetto L. A validated LC/UV method for the determination of four adulterating drugs in herbal slimming capsules. J Pharm Biomed Anal. 2016 Jan 5;117:436-45. doi: 10.1016/j.jpba.2015.09.027. Epub 2015 Sep 26. PubMed PMID: 26454104.

17: Szymanski C, Maréchaux S, Bruneval P, Andréjak M, de Montpréville VT, Belli E, Tribouilloy C. Sub-aortic obstruction of left ventricular outflow tract secondary to benfluorex-induced endocardial fibrosis. Int J Cardiol Heart Vasc. 2015 Sep 21;9:67-69. doi: 10.1016/j.ijcha.2015.09.003. eCollection 2015 Dec 7. PubMed PMID: 28785710; PubMed Central PMCID: PMC5497322.

18: Choisy H, Ségal A. [From ergot of rye to Mediator]. Hist Sci Med. 2014 Oct-Dec;48(4):537-9. French. PubMed PMID: 25962221.

19: Ennezat PV, Bruneval P, Maréchaux S, Bellemin JP, Senellart F, Arnaud-Crozat E, Ramadan R, Obadia JF, Touati G, Fleury JP, Tribouilloy C. Operative finding of aortic cusp prolapse in benfluorex-induced aortic regurgitation. Int J Cardiol. 2015;186:231-2. doi: 10.1016/j.ijcard.2015.03.191. Epub 2015 Mar 18. PubMed PMID: 25828122.

20: Malergue MC, Bruneval P, Czitrom D, Ennezat PV. Fatal dynamic mitral regurgitation as a presentation of benfluorex-Induced valvular heart toxicity. Int J Cardiol. 2015 Apr 1;184:549-51. doi: 10.1016/j.ijcard.2015.03.009. Epub 2015 Mar 3. PubMed PMID: 25767015.